1033.0500 -1.45 (-0.14%)
NSE Sep 17, 2025 09:40 AM
Volume: 61,553
 

1033.05
-0.14%
IDBI Capital
Most awaited approvals start to roll out, giving us confidence in the future pipeline getting launched. After getting a green chit from US FDA for the Moraiya facility, and first approval of Levofloxacin injection was received on June 2, post which Cadila received FTF of gLialda...
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended